Related Experiment Video

Updated: Mar 14, 2026

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature
10:07

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature

Published on: December 26, 2017

14.2K

Treatment of diabetes: Crossing to the other side

Nikitas P Skliros1, Charalambos Vlachopoulos1, Dimitrios Tousoulis1

  • 1Hippokration Hospital, University of Athens, 1st Department of Cardiology, Athens, Greece.

Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese
|October 1, 2016
PubMed

Insights

New antidiabetic medications for type 2 diabetes mellitus are being evaluated for cardiovascular safety and efficacy. Recent trials focus on proving superiority over standard treatments, with ongoing studies to reveal future trends.

Area of Science:

  • Endocrinology
  • Cardiology
  • Clinical Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) impacts over 400 million globally, with cardiovascular disease as a primary complication.
  • Evaluating the safety and effectiveness of T2DM medications is complex.
  • Non-inferiority trials traditionally assess drug safety before clinical adoption.

Purpose of the Study:

  • To review recent clinical trial results for T2DM medications.
  • To discuss the evolving trend towards superiority trials.
  • To anticipate outcomes from ongoing T2DM drug trials.

Main Methods:

  • Review of recent large clinical trials in T2DM.
  • Analysis of non-inferiority and superiority trial designs.
  • Synthesis of current research trends and future projections.

Main Results:

  • Recent trials increasingly employ superiority designs to demonstrate added benefits.
  • Non-inferiority trials remain crucial for initial safety assessments.
  • The landscape of T2DM drug evaluation is shifting towards proving enhanced therapeutic value.

Conclusions:

  • Superiority trials are becoming the standard for new T2DM medications.
  • Future research will likely focus on drugs offering additional cardiovascular benefits.
  • Understanding trial methodologies is key to interpreting T2DM treatment advancements.
Keywords:
Antidiabetic drugsCardiovascular diseaseCardiovascular outcome trialsCardiovascular safetyType 2 diabetes mellitus

More Related Videos

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.7K
Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise05:06

Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise

Published on: July 14, 2023

2.5K

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.8K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.3K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.6K
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
14.8K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.0K